Aulos Bioscience

Aulos Bioscience is an immuno-oncology company that aims to revolutionize cancer patient care through its computationally designed IL-2 therapeutics. The company's flagship clinical candidate, AU-007, has been engineered to leverage a patient's own IL-2 to induce tumor killing while minimizing associated toxicities. Founded in 2020 by Biolojic Design and ATP, Aulos Bioscience secured a substantial $40M Series A investment from Apple Tree Partners. The startup, based in the United States, combines world-class machine learning with a deep understanding of the immune system and is poised to make significant contributions to biotechnology and healthcare. Aulos Bio's focus on leveraging the power of the immune system to combat cancer positions it as a promising player in the evolving immuno-oncology landscape. With its groundbreaking approach and strong financial backing, Aulos Bioscience presents an exciting opportunity for potential investors and stakeholders in the cancer care industry.